Literature DB >> 26645326

CD25 (IL-2R) expression correlates with the target cell induced cytotoxic activity and cytokine secretion in human natural killer cells.

Karolina Rudnicka1, Agnieszka Matusiak1, Magdalena Chmiela1.   

Abstract

Cytotoxic activity is one of the major functions of Natural Killer (NK) cells and is a critical effector mechanism of innate immune responses against infected or cancer cells. A variety of assays have been developed to determine NK cell cytotoxic activity, however a receptor-based screening tool is still lacking. Here, we propose the CD25 receptor as a candidate for NK cell cytotoxicity marker. We have verified that there is a correlation between classic target cell induced cytotoxicity markers and the CD25 expression on NK cells. Non-adherent lymphocyte fractions pre-stimulated with Escherichia coli O55:B5 lipopolysaccharide were co-cultured with settled HeLa targets in a four hour long cytotoxic assay. The cytotoxic effect was evaluated by MTT reduction assay and quantification of soluble cytotoxicity markers (granzyme B, FasL, caspase-8, IFN-γ and IL-2) was done by ELISA. Lymphocytes were stained with anti-CD3-Cy-5, anti-CD56/CD16/Nkp46-FITC and anti-CD25-PE antibodies and analyzed by flow cytometry. We observed that the CD25 expression exclusively on the CD3(-)CD56(+)CD25(+) NK cells was positively correlated with their cytotoxic function evaluated by the MTT test (r = 0.68), the upregulation of granzyme B (r = 0.89), IL-2 (r = 0.78) and IFN-γ (r = 0.57), however, it was not positively correlated with FasL and caspase-8. We conclude that the CD25 expression might serve as an in vitro receptor-based screening tool for NK cell activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26645326     DOI: 10.18388/abp.2015_1152

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  7 in total

1.  [Cbl-b gene silencing enhances H9 T lymphocyte-mediated killing of human laryngeal squamous cancer Hep-2 cells].

Authors:  Saiming Chen; Zhiqun Li; Limin Zhou; Yunxia Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

2.  Differential pulmonic NK and NKT cell responses in Schistosoma japonicum-infected mice.

Authors:  Hefei Cha; Wenjuan Qin; Quan Yang; Hongyan Xie; Jiale Qu; Mei Wang; Daixiong Chen; Fang Wang; Nuo Dong; Longhua Chen; Jun Huang
Journal:  Parasitol Res       Date:  2016-11-30       Impact factor: 2.289

3.  Natural Killer Cells Integrate Signals Received from Tumour Interactions and IL2 to Induce Robust and Prolonged Anti-Tumour and Metabolic Responses.

Authors:  Nidhi Kedia-Mehta; Chloe Choi; Aisling McCrudden; Elisabeth Littwitz-Salomon; Proinnsias G Fox; Clair M Gardiner; David K Finlay
Journal:  Immunometabolism       Date:  2019-09-25

4.  Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.

Authors:  Henna Kasanen; Micaela Hernberg; Siru Mäkelä; Oscar Brück; Susanna Juteau; Laura Kohtamäki; Mette Ilander; Satu Mustjoki; Anna Kreutzman
Journal:  Cancer Immunol Immunother       Date:  2020-02-08       Impact factor: 6.968

Review 5.  Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer.

Authors:  Arturo Valle-Mendiola; Adriana Gutiérrez-Hoya; María del Carmen Lagunas-Cruz; Benny Weiss-Steider; Isabel Soto-Cruz
Journal:  Mediators Inflamm       Date:  2016-05-12       Impact factor: 4.711

6.  Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.

Authors:  Roberta Sommaggio; Elisa Cappuzzello; Anna Dalla Pietà; Anna Tosi; Pierangela Palmerini; Debora Carpanese; Lorenzo Nicolè; Antonio Rosato
Journal:  Oncoimmunology       Date:  2020-06-11       Impact factor: 8.110

7.  Characterization of Surface Receptor Expression and Cytotoxicity of Human NK Cells and NK Cell Subsets in Overweight and Obese Humans.

Authors:  Wiebke Naujoks; Dagmar Quandt; Anja Hauffe; Heike Kielstein; Ina Bähr; Julia Spielmann
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.